via MD Anderson
A new RNA-based control switch could be used to trigger production of therapeutic proteins to treat cancer or other diseases.
Researchers at MIT and Harvard University have designed a way to selectively turn on gene therapies in target cells, including human cells. Their technology can detect specific messenger RNA sequences in cells, and that detection then triggers production of a specific protein from a transgene, or artificial gene.
Because transgenes can have negative and even dangerous effects when expressed in the wrong cells, the researchers wanted to find a way to reduce off-target effects from gene therapies. One way of distinguishing different types of cells is by reading the RNA sequences inside them, which differ from tissue to tissue.
By finding a way to produce transgene only after “reading” specific RNA sequences inside cells, the researchers developed a technology that could fine-tune gene therapies in applications ranging from regenerative medicine to cancer treatment. For example, researchers could potentially create new therapies to destroy tumors by designing their system to identify cancer cells and produce a toxic protein just inside those cells, killing them in the process.
“This brings new control circuitry to the emerging field of RNA therapeutics, opening up the next generation of RNA therapeutics that could be designed to only turn on in a cell-specific or tissue-specific way,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering and the senior author of the study.
This highly targeted approach, which is based on a genetic element used by viruses to control gene translation in host cells, could help to avoid some of the side effects of therapies that affect the entire body, the researchers say.
Evan Zhao, a research fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University, and Angelo Mao, an MIT postdoc and technology fellow at the Wyss Institute, are the lead authors of the study, which appears today in Nature Biotechnology.
Messenger RNA (mRNA) molecules are sequences of RNA that encode the instructions for building a particular protein. Several years ago, Collins and his colleagues developed a way to use RNA detection as a trigger to stimulate cells to produce a specific protein in bacterial cells. This system works by introducing an RNA molecule called a “toehold,” which binds to the ribosome-binding site of an mRNA molecule that codes for a specific protein. (The ribosome is where proteins are assembled based on mRNA instructions.) This binding prevents the mRNA from being translated into protein, because it can’t attach to a ribosome.
The RNA toehold also contains a sequence that can bind to a different mRNA sequence that serves as a trigger. If this target mRNA sequence is detected, the toehold releases its grip, and the mRNA that had been blocked is translated into protein. This mRNA can encode any gene, such as a fluorescent reporter molecule. That fluorescent signal gives researchers a way to visualize whether the target mRNA sequence was detected.
In the new study, the researchers set out to try to create a similar system that could be used in eukaryotic (non-bacterial) cells, including human cells.
Because gene translation is more complex in eukaryotic cells, the genetic components that they used in bacteria couldn’t be imported into human cells. Instead, the researchers took advantage of a system that viruses use to hijack eukaryotic cells to translate their own viral genes. This system consists of RNA molecules called internal ribosome entry sites (IRES), which can recruit ribosomes and initiate translation of RNA into proteins.
“These are complicated folds of RNA that viruses have developed to hijack ribosomes because viruses need to find some way to express protein,” Zhao says.
The researchers started with naturally occurring IRES from different types of viruses and engineered them to include a sequence that binds to a trigger mRNA. When the engineered IRES is inserted into a human cell in front of an output transgene, it blocks translation of that gene unless the trigger mRNA is detected inside the cell. The trigger causes the IRES to recover and allows the gene to be translated into protein.
The researchers used this technique to develop toeholds that could detect a variety of different triggers inside human and yeast cells. First, they showed that they could detect mRNA encoding viral genes from Zika virus and the SARS-CoV-2 virus. One possible application for this could be designing T cells that detect and respond to viral mRNA during infection, the researchers say.
They also designed toehold molecules that can detect mRNA for proteins that are naturally produced in human cells, which could help to reveal cell states such as stress. As an example, they showed they could detect expression of heat shock proteins, which cells make when they are exposed to high temperatures.
Lastly, the researchers showed that they could identify cancer cells by engineering toeholds that detect mRNA for tyrosinase, an enzyme that produces excessive melanin in melanoma cells. This kind of targeting could enable researchers to develop therapies that trigger production of a protein that initiates cell death when cancerous proteins are detected in a cell.
“The idea is that you would be able to target any unique RNA signature and deliver a therapeutic,” Mao says. “This could be a way of limiting expression of the biomolecule to your target cells or tissue.”
The new technique represents “a conceptual quantum leap in controlling and programming mammalian cell behavior,” says Martin Fussenegger, a professor of biotechnology and bioengineering at ETH Zurich, who was not involved in the research. “This novel technology sets new standards by which human cells could be treated to sense and react to viruses such as Zika and SARS-CoV-2.”
The Latest on: Targeted RNA therapeutics
- Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeuticson May 26, 2022 at 4:32 am
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference ...
- Myeloid Therapeutics to Participate at Investor Conferences in June 2022on May 24, 2022 at 1:15 pm
Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will participate in the follo ...
- Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summiton May 19, 2022 at 9:20 pm
GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development ...
- Remix Therapeutics raises $70m to develop drugs that reprogram RNAon May 17, 2022 at 4:00 am
Remix Therapeutics is cashing in on biotech investors’ continued interest in RNA. The Cambridge startup has raised 70 million in series B financing to develop drugs that “reprogram RNA processing” to ...
- Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdownon May 16, 2022 at 4:48 am
Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Dyne ...
- Sirnaomics: a unique, clinical-phase RNA therapeutic innovator on the global stageon May 16, 2022 at 4:44 am
Sirnaomics is poised to improve outcomes in therapeutic areas such as oncology and fibrosis with a pipeline of prospects built on proprietary delivery technology platforms able to deliver siRNAs and ...
- RNA Based Therapeutic Market To Be Reach CAGR of 17.6% By 2030 | Alnylam Pharmaceuticals, Silence Therapeutics, Arbutus Biopharmaon May 12, 2022 at 3:40 am
The RNA based therapeutics has been explored as a promising ... Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist ...
- The promise of RNA medicine is targeted and personalizedon May 11, 2022 at 8:23 pm
The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.
- Arrakis Therapeutics to Participate in Upcoming May Investor Conferenceson May 10, 2022 at 5:01 am
May 10, 2022--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that ...
- Cancer Therapeutics Target the Undruggable, Confront Other Bugbearson May 6, 2022 at 6:39 am
Messenger RNA lasts only a day or two in cells ... and non-small cell lung cancer. Orum Therapeutics develops tumor-directed targeted protein degraders (TPDs) to treat cancer.
via Bing News
The Latest on: Targeted RNA therapeutics
via Google News